Our investigation provides a proof of concept that immunoliposome delivery of the Cas9gRNA-hIL30 complex for IL30 genome editing at the tumor site is a clinically valuable tool for the safe and effective immunotherapy of PC. This evidence concerns the gene IL27 and pachyonychia congenita.